RecruitingNCT03019757

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease


Sponsor

Douglas Scharre

Enrollment

76 participants

Start Date

Aug 30, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study aims to find better ways to tell apart three brain conditions — Alzheimer's disease, Lewy body dementia, and Parkinson's disease — which can look similar but require different treatments. **You may be eligible if...** - You have been diagnosed with Alzheimer's disease, Lewy body dementia, or Parkinson's disease based on standard clinical criteria - You are able to complete study tasks (scoring at least 10 on the Mini Mental State Examination) - You have been on stable memory or psychiatric medications for at least 4 weeks - You have a family member or close contact who sees you at least 4 days per week - You have adequate vision and hearing for testing **You may NOT be eligible if...** - You have another condition that could explain or complicate your memory problems - You have a serious active medical condition that would prevent participation - You are pregnant or breastfeeding - You have severe kidney disease - English is not your first language or you have fewer than 12 years of education - You have taken part in an experimental study targeting amyloid plaques (unless you only received a placebo) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONDaTscan

A functional imaging of the dopamine transporter using the radioligand \[123I\]FP-CIT

RADIATIONF18-AV-45

A brain scan to to measure the extent of amyloid deposition

RADIATIONFDG-PET

a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)

GENETICAPOE genotype

10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.

PROCEDUREPolysomnogram

Overnight sleep study

BEHAVIORALClinical Assessment

Clinical assessments include cognitive, behavioral, and motor evaluations


Locations(1)

The Ohio State University

Columbus, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03019757


Related Trials